Protocols
7 protocol(s) meet the specified criteria
Disease Site: Unknown Sites
Protocol No.TitleStatus
2843-1001A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects with Relapsed/Refractory Advanced and/or Metastatic Solid TumorsOpen
ANHL1522A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP-specific Cytotoxic T-Lymphocytes (LMP-TC, IND # 17068) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)Open
APEC1621SCNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)Open
C-145-03A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckOpen
FADOI03-2016Apixaban for the Treatment of Venous Thromboembolism in Patients with Cancer: a Prospective Randomized Open Blinded End-Point (PROBE) Study - The Caravaggio StudyOpen
NANT17-01/MIBG-DA Phase I Study of 131I-MIBG With Dinutuximab for Relapsed/Refractory NeuroblastomaOpen
NCI-10057-CIRBA Phase II Study of Talimogene Iaherparepvec Followed by Talimogene Iaherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin TumorsOpen